Project Grant R01CA296813
Award Date
4/4/25
Completion Date
3/31/30
Dollars Obligated
$553K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,831 to the University of Colorado-Denver to develop chimeric antigen receptor (CAR) phagocytes as a novel treatment for glioblastoma, a highly aggressive type of brain cancer. The 5-year project aims to investigate the use of engineered immune cells to target and eliminate glioblastoma tumors, with a focus on pediatric high-grade gliomas. The research will explore the potential...
The National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $652,725 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for treating glioblastoma, a deadly brain cancer. The funded project aims to test the safety and feasibility of injecting CAR T-cells engineered to secrete a T-cell engaging antibody (CARV3.TEAM-E...
The National Cancer Institute awarded a $701,408 Project Grant (CFDA 93.395 Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on enhancing the response to immune checkpoint blockade therapy in central nervous system metastases from breast cancer. The project aims to characterize mechanisms of resistance to immunotherapy in central nervous system metastases by profiling cancer and immune cells using...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $634,894 to The Washington University in St. Louis to conduct research aimed at improving survival for patients with locally advanced cervical cancer. The key objectives are to determine if an "Accelerated Brachytherapy-Forward Chemoradiation Therapy (ABC-RT)" approach can safely shorten overall treatment time and maximize anti-tumor immune response, as well as...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
The National Cancer Institute (NCI) awarded a $227,941 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Washington University to develop and pilot an electronic health record (EHR)-based communication tool, the "Cancer Care Companion," to improve information exchange and self-management for families of children with cancer. The project aims to engage parents and pediatric oncology clinicians to co-develop the tool, which will adapt the...
The National Cancer Institute (NCI) awarded a $657,121 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, FL. The project aims to evaluate the use of polarized conventional type I dendritic cell (cDC1) therapy, primed with HER2 and HER3 antigens, as a potential treatment and prevention strategy for leptomeningeal disease (LMD) in breast cancer patients. The research team will determine the cellular and...
This Project Grant award in the amount of $639,004 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research on a novel long-acting interleukin-7 (NT-I7) therapy to enhance immune response and improve survival in patients with glioblastoma. The project aims to evaluate the safety and efficacy of combining NT-I7 with anti-PD-1 checkpoint blockade in a Phase II clinical trial, as well as conduct preclinical studies to understand the mechanisms by which NT-I7...
This $931,841 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the development of next-generation immunotherapies for pediatric cancers at Stanford University. The award aims to leverage the university's expertise in cellular and molecular immunology, synthetic biology, and protein engineering to create safer and more potent immunotherapies for children's cancers. Key focus areas include overcoming suppressive tumor...
This federal Project Grant award of $1,260,842 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Duke University's research on the clinical neuroimmunology of CCL3 in brain tumors. The project aims to advance the understanding and treatment of malignant primary brain tumors, which are the leading cause of cancer deaths in children and young adults. The research will explore the role of the chemokine CCL3 in brain tumor biology and its potential as a...